Blog
Oveporexton (TAK-861): A First-in-Class Orexin Agonist for Narcolepsy Type 1 and Its ChemAIRS® Retrosynthesis
Retrosynthetic analysis of oveporexton (TAK-861), the first-in-class OX2R agonist for narcolepsy type 1, now under FDA Priority Review, planned with ChemAIRS®.
Synthesis of Vepdegestrant (ARV-471): ChemAIRS® Route Design for the First Approved PROTAC
Synthesis of vepdegestrant (ARV-471): ChemAIRS® retrosynthetic analysis of the first FDA-approved PROTAC degrader for ESR1-mutated breast cancer.
Synthesis of Daraxonrasib (RMC-6236): ChemAIRS® Retrosynthetic Analysis Behind the FDA-Accepted RAS(ON) Inhibitor
Synthesis of daraxonrasib (RMC-6236): ChemAIRS® proposes discovery and process routes for the RAS(ON) inhibitor now under FDA review.
ChemAIRS®-Proposed Synthesis of Zidesamtinib (NVL-520), the Newly Approved TRK-Sparing ROS1 Inhibitor
ChemAIRS-proposed synthesis of zidesamtinib (NVL-520): two routes to the macrocyclic ROS1 inhibitor just approved for previously treated ROS1+ NSCLC.
ChemAIRS®-Proposed Synthesis of Sonrotoclax (BGB-11417): From Nine Steps to Four, With Late-Stage Head Group Installation
ChemAIRS® generated a route to sonrotoclax (BGB-11417) that cuts the disclosed synthesis from nine steps to four, by installing the P2 head group last instead of carrying it through the whole sequence.
Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453)
Using ChemAIRS, we explored synthetic pathways to AbbVie’s Surzetoclax (ABBV-453), a highly complex, next-generation BCL-2 inhibitor weighing nearly 1000 Da with multiple fused tricyclic and macrocyclic rings. In High-Risk Retrosynthesis mode, ChemAIRS showcased its ability to navigate this molecular complexity. Guided by human insight, the AI-driven retrosynthesis platform delivered a streamlined, convergent, and experimentally executable synthesis, highlighting the power of human-AI collaboration in modern drug discovery.